This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


Laszlo Kiss
Executive Director at Pfizer Ventures


Laszlo Kiss, PHD is Executive Director at Pfizer Ventures. Laszlo is responsible for identifying, evaluating, making and managing equity investments aligned with the future directions of Pfizer. He currently has responsibility for Pfizer’s investments in Accelerator NYC, Aquinnah, Autifony, Cortexyme, Magnolia, Simcha, System1, Triplet and Yumanity. Laszlo has over 20 years of drug discovery, development and management experience. He has a successful track record in leading CNS, CV and Rare Disease drug discovery programs from early exploratory research through clinical development. Prior to joining Pfizer, Laszlo held a variety of roles at Bristol-Myers Squibb, Essen Biosciences, and Merck & Co.

Agenda Sessions

  • Platform technologies in drug development. What are the trends? What deal models are applicable. Co-development, out-licensing, other? What factors are relevant. Deal valuation, deal stage, players? What are the challenges faced? Path forward?